Dexcom (Nasdaq:DXCM) shares are up today on second-quarter results that topped the consensus forecast. Shares of DXCM rose 2.3% at $132.35 apiece after the market closed yesterday. By the next afternoon, DXCM shares were up more than 4% to $134.71 apiece. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device […]
U.S. military to test Bexson Biomedical ketamine delivery device
Bexson Biomedical announced that the U.S. military intends to field-test its Akeso wearable ketamine delivery device. Akeso, a ruggedized version of Bexson Biomedical’s wearable infusion device, utilizes Sevalent technology. Sevalent, Bexson’s proprietary formulation platform can work with small molecules across a broad range of drug classes. It enables subcutaneous intravenous (IV) therapy delivery. Bexson management […]
UroGen to raise $120M to support sustained release hydrogel delivery platform
UroGen Pharma (Nasdaq:URGN) announced that it entered into a securities purchase agreement worth approximately $120 million. The placement includes the issuance of nearly 12.6 million ordinary shares or pre-funded warrants priced at $9.54 per share. UroGen expects the placement to close on or about today, subject to customary closing conditions. RA Capital Management and Great […]
Report: Insulet prevails over Medtrum in France patent spat
According to a report in Europe, a Paris court found that Medtrum’s latest insulin pumps infringe an Insulet (Nasdaq:PODD) patent. JUVE Patent reported that earlier this month, the Judicial Court of Paris declared the infringement. The court found that Medtrum’s newest pump base and patch reservoir models violate the EP2438957B1 patent from Insulet. In declaring […]
Know Labs has more positive data for its non-invasive glucose monitor
Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology. Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The […]
B. Braun recalls some two-piece syringes due to potential packaging barrier damage
B. Braun issued an urgent field safety notice in Europe related to potential issues with certain two-piece syringes. The company’s notice said it decided to proactively recall a batch combination of the syringes. B. Braun identified a number of batches of its Exadoral, Henke-JECT, Norm-Ject and Injekt devices. In the course of postmarket surveillance and […]
Research highlights cost savings from DarioHealth digital diabetes therapeutic
DarioHealth (Nasdaq:DRIO) announced today that a new analysis demonstrated a significant cost reudction for users of its digital therapeutic platform. Sanofi U.S. conducted the analysis, which showed lower costs of care for DarioHealth users compared to non-users with type 2 diabetes. The study used matched claims to show an estimated $5,077 in medical cost savings […]
Feasibility study backs Glucotrack implantable CGM
Glucotrack (Nasdaq:GCK) announced today that it completed a feasibility study for its implantable continuous glucose monitor (CGM). Rutherford, New Jersey-based Glucotrack designed its CGM for patients with type 1 and type 2 insulin-dependent diabetes. The company said late last year that it planned to expand its product pipeline with an R&D program. The program centers around developing […]
FDA clears updated BD Alaris infusion system after long-term commercial hold
BD (NYSE:BDX) announced today that the FDA granted 510(k) clearance for its updated Alaris infusion system. Shares of BDX closed out Friday evening priced at $264.84 each. They ticked up significantly after market close on the back of the Alaris news, rising 5.9% to $280.40 apiece. Clearance enables both remediation and a return to full […]
RenovoRx, Imugene collab on oncolytic virus therapy delivery
RenovoRx (Nasdaq:RNXT) announced that it entered into a strategic research collaboration with Imugene to optimize oncolytic virus therapy delivery. Utilizing RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform), the companies hope to enhance the treatment of difficult-to-access tumors. “Our collaboration with Imugene is an important milestone for RenovoRx as we expand our pipeline from exclusively treating locally […]